Health Care [ 1/12 ] | Pharmaceuticals [ 10/73 ]
NASDAQ | Common Stock
Sonoma Pharmaceuticals, Inc. develops and produces stabilized hypochlorous acid (HOCl) products for wound and eye care, oral and nasal care, podiatry, animal health care, and dermatological conditions in the United States, Europe, Asia, Latin America, and internationally.
It offers Lumacyn, a skin toner; Regenacyn, a prescription scar gel; Reliefacyn to alleviate red bumps, rashes, shallow skin fisures, sunburn, peeling, and eczema/atopic dermatitis; Gramaderm for the treatment of topical mild to moderate acne; Epicyn, an antimicrobial facial cleanser; Levicyn, an HOCl based prescription and over-the-counter product used to relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and Pediacyn, an atopic dermatitis hydrogel.
The company also provides Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a range of pathogens; Ocucyn eyelid and eyelash cleanser; Ocudox for eye care; Sinudox for nasal irrigation; Microdacyn60 oral care solution to treat mouth and throat infections; and Podiacyn, a foot care product.
In addition, it offers MicrocynAH, an HOCl-based solution used to relieve common symptoms of hot spots, scratches, skin rashes, post-surgical sites, and irritated animal skin; MicrocynVS, an animal care product; Nanocyn, a hospital-grade disinfectant; Acuicyn, a solution for the treatment of blepharitis and the daily hygiene of eyelids and lashes; MucoClyns, a disinfectant; and Endocyn, a root canal irrigation solution.
The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016.
Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Boulder, Colorado.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 4, 25 | -0.32 Increased by +45.76% | -0.05 Decreased by -540.00% |
| Aug 7, 25 | -0.76 Decreased by -985.71% | -0.51 Decreased by -49.02% |
| Jun 17, 25 | -0.48 Decreased by -585.71% | -0.04 Decreased by -1.10 K% |
| Feb 5, 25 | -0.63 Decreased by -687.50% | -0.60 Decreased by -5.00% |
| Nov 7, 24 | -0.59 Decreased by -103.45% | -0.80 Increased by +26.25% |
| Aug 8, 24 | -0.07 Increased by +74.96% | -0.06 Decreased by -16.67% |
| Jun 17, 24 | -0.07 Increased by +77.42% | -0.17 Increased by +58.82% |
| Feb 8, 24 | -0.08 Increased by +87.10% | -0.21 Increased by +61.90% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 25 | 5.60 M Increased by +56.58% | -534.00 K Increased by +12.46% | Decreased by -9.53% Increased by +44.09% |
| Jun 30, 25 | 4.01 M Increased by +18.40% | -1.24 M Decreased by -8.57% | Decreased by -30.91% Increased by +8.30% |
| Mar 31, 25 | 3.75 M Increased by +9.16% | -776.00 K Increased by +27.27% | Decreased by -20.67% Increased by +33.38% |
| Dec 31, 24 | 3.56 M Increased by +13.58% | -928.00 K Decreased by -7.16% | Decreased by -26.04% Increased by +5.65% |
| Sep 30, 24 | 3.58 M Increased by +31.05% | -610.00 K Increased by +58.89% | Decreased by -17.04% Increased by +68.63% |
| Jun 30, 24 | 3.39 M Decreased by -1.05% | -1.14 M Increased by +19.39% | Decreased by -33.71% Increased by +18.54% |
| Mar 31, 24 | 3.44 M Increased by +14.10% | -1.07 M Increased by +18.43% | Decreased by -31.03% Increased by +28.51% |
| Dec 31, 23 | 3.14 M Increased by +6.59% | -866.00 K Increased by +55.34% | Decreased by -27.60% Increased by +58.10% |